Press Releases Abivax

Equities

ABVX

FR0012333284

Real-time Euronext Paris Other stock markets 09:51:02 2024-05-15 am EDT			5-day change	1st Jan Change
13.18 ^EUR	0.00%		-2.08%	+34.22%

May. 08	Abivax: four abstracts to be presented on obefazimod	CF
May. 08	Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024	May. 08	EQ
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents	May. 07	EQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 08	AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 05	EQ
Abivax reports 2023 financial results and operational update	Apr. 02	EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)	Feb. 14	AQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)	Feb. 13	EQ
Abivax appoints Ana Sharma as Vice President, Global Head of Quality	Feb. 07	EQ
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease	Feb. 05	AQ
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease	Feb. 02	EQ
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024	Jan. 24	EQ
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months	Jan. 22	EQ
Abivax 2024 Financial Communication Calendar	Jan. 04	EQ
Abivax announces the resumption of its liquidity contract	Nov. 21	EQ
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference	Nov. 14	EQ
Abivax Announces $235.8 Million IPO	23-10-27	AQ
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market	23-10-24	EQ
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market	23-10-23	AQ
Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris	23-10-23	AQ
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris	23-10-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Abivax

Equities

ABVX

FR0012333284

Press Releases

Filters